Although it is generally well-known that smoking poses numerous risks to physical health and well-being, it carries additional risks for patients with cancer. Therefore, smoking cessation is of particular concern among this patient population. At the NCCN 2025 Annual Conference, a panel convened to discuss the current evidence surrounding smoking-associated risks for patients with cancer, the benefits of smoking cessation specific to them, and evidence-based approaches to improve rates of smoking cessation.
Disclosures: Dr. Davis has disclosed receiving consulting fees from Currax Pharmaceuticals LLC; receiving grant/research support from Delfi Diagnostics, Inc.; and owning equity interest/stock options in Predictably Human. Dr. Reid has disclosed serving as a scientific advisor for Johnson & Johnson. The remaining presenters have disclosed no relevant financial relationships.